ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

National Multicenter Trial Evaluating Two Treatments in Patients with Primary Human Immunodeficiency Virus (HIV-1) Infection

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Darunavir-cobicistat
Drug: Dolutegravir
Drug: Emtricitabine-Tenofovir

First Posted Date: 2016-12-09

Last Posted Date: 2024-12-27

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 101

Registration Number: NCT02987530

Locations: 🇫🇷
Hopital Bicetre, All the regions of the country (40 centers), France

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

Phase 1

Terminated

Conditions: HIV-1-infection

Interventions: Drug: Vedolizumab 300 MG [Entyvio]
Biological: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine
Other: Placebo
Biological: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab

First Posted Date: 2016-11-23

Last Posted Date: 2019-08-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 1

Registration Number: NCT02972450

Locations: 🇨🇭
CHUV, Lausanne, Switzerland
🇬🇧
Chelsea & Westminster Hospital, London, United Kingdom

Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission

Phase 4

Conditions: Hepatitis B Chronic Infection
Pregnancy

Interventions: Drug: Tenofovir disoproxil fumarate
Device: Rapid tests HBe Ag

First Posted Date: 2016-10-19

Last Posted Date: 2019-10-16

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 933

Registration Number: NCT02937779

Locations: 🇰🇭
Kampong Cham Provincial Hospital, Kampong Cham, Cambodia
🇰🇭
Calmette Hospital, Phnom Penh, Cambodia
🇰🇭
National Mother and Child Health Center, Phnom Penh, Cambodia

Gut-Associated Lymphocyte Trafficking

Not Applicable

Completed

Conditions: HIV-1 Infection

Interventions: Other: Peripheral blood and intestinal biopsies will be collected

First Posted Date: 2016-09-19

Last Posted Date: 2022-01-14

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 80

Registration Number: NCT02906137

Locations: 🇫🇷
Hôpital Purpan - Service de Médecine Interne, Toulouse, France
🇫🇷
Hôpital Purpan - Service des maladies Infectieuses, Toulouse, France

Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity

Completed

Conditions: HIV Infection

First Posted Date: 2016-09-01

Last Posted Date: 2018-09-28

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 22

Registration Number: NCT02886416

Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C

Conditions: Exposure to Hepatitis C Virus

First Posted Date: 2016-07-11

Last Posted Date: 2017-04-10

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 550

Registration Number: NCT02826447

Locations: 🇪🇬
Ain Shams University Teaching Hospital, Cairo, Egypt

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Dolutegravir 50 mg
Drug: Efavirenz 400 mg
Drug: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg

First Posted Date: 2016-05-19

Last Posted Date: 2021-08-31

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 616

Registration Number: NCT02777229

Locations: 🇨🇲
Military Hospital, Yaoundé, Cameroon
🇨🇲
Hopital Central, Yaoundé, Cameroon
🇨🇲
Cité verte Hospital, Yaoundé, Cameroon

Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors

Phase 2

Completed

Conditions: Maternal-fetal Infection Transmission

Interventions: Drug: darunavir monotherapy

First Posted Date: 2016-04-14

Last Posted Date: 2021-08-06

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 91

Registration Number: NCT02738502

Locations: 🇫🇷
Hôpital Saint André, Bordeaux, France
🇫🇷
Hôpital Louis Mourier, Colombes, France
🇫🇷
Hôpital Bicêtre, Le Kremlin Bicêtre, France

and more 20 locations

CLEAC (Comparison of Late Versus Early Antiretroviral Therapy in HIV-infected Children)

Not Applicable

Conditions: HIV Infection

Interventions: Other: Blood draw

First Posted Date: 2016-02-05

Last Posted Date: 2019-01-18

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 80

Registration Number: NCT02674867

Locations: 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷
Hôpital Louis Mourier, Colombes, France
🇫🇷
Centre Hospitalier Intercommunal, Créteil, France

and more 8 locations

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Grazoprevir/Elbasvir
Drug: Sofosbuvir
Drug: Ribavirin

First Posted Date: 2016-01-06

Last Posted Date: 2017-06-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 26

Registration Number: NCT02647632

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy